TY - JOUR
T1 - Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
AU - Sgouros, George
AU - Hobbs, Robert F.
AU - Atkins, Francis B.
AU - Van Nostrand, Douglas
AU - Ladenson, Paul W.
AU - Wahl, Richard L.
N1 - Funding Information:
Supported by NIH NCI grant No. R01 CA116477. G.Sgouros(*).R.F.Hobbs.R.L.Wahl The Russell H. Morgan Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA e-mail: [email protected]
PY - 2011/5
Y1 - 2011/5
N2 - Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.
AB - Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.
KW - Positron emission tomography
KW - Radioiodine therapy
KW - Three-dimensional radiobiological dosimetry
KW - Thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=79957962933&partnerID=8YFLogxK
U2 - 10.1007/s00259-011-1769-1
DO - 10.1007/s00259-011-1769-1
M3 - Review article
C2 - 21484384
AN - SCOPUS:79957962933
SN - 1619-7070
VL - 38
SP - S41-S47
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - SUPPL. 1
ER -